rs201892814

Variant summary

Our verdict is Pathogenic. The variant received 8 ACMG points: 8P and 0B. PP1_ModeratePP4_ModeratePM3PVS1_Moderate

This summary comes from the ClinGen Evidence Repository: The NM_000070.3: c.1746-20C>G variant occurs in intron 13 of the CAPN3 gene. The filtering allele frequency for this variant is 0.006051 in gnomAD v2.1.1 European (non-Finnish) genomes (the lower threshold of the 95% CI of 172/31388), which is higher than the LGMD VCEP threshold of 0.001 for BS1; in total, three homozygous individuals are also observed. However, this variant may act as a hypomorphic allele, and the VCEP opted not to apply this code (BS1 exception). RNAseq/cDNA analysis of muscle from patients carrying one copy of the variant suggests that it results in aberrant splicing, the inclusion of various portions of intron 13, and premature truncation (PMID:20635405, 35731190). An earlier study concluded the variant does not affect splicing (PMID:17979987); however, later investigations showed that the aberrantly spliced transcripts are variably expressed and not always detectable even when splicing-specific PCR is used, possibly due to nonsense-mediated mRNA decay (PMID:20635405) (PVS1_RNA_Moderate). The c.1746-20C>G variant has been detected with a second CAPN3 variant in at least 34 individuals with LGMD (PMID:37589857, 20635405, 17979987, 17157502, 35731190), including confirmed in trans with a pathogenic variant in five cases (c.550delA p.(Thr184ArgfsTer36), 4.0 pts, PMID:20635405, 35731190; c.643_663del p.(Ser215_Gly221del): 1.0 pt, PMID:35731190) (PM3_Very Strong). The variant was also reported to co-segregate with autosomal recessive disease in four affected family members from three families (PP1_Moderate; PMID:37589857, 20635405, 35731190). Several patients with the c.1746-20C>G variant and a second CAPN3 variant displayed progressive limb girdle muscle weakness or clinical suspicion of limb-girdle muscular dystrophy as well as significantly reduced or absent expression of calpain-3, which is specific for CAPN3-related LGMD (PP4_Moderate; PMID:20635405). While two homozygous patients with a mild phenotype have been reported (PMID:35731190), the number of apparently unaffected homozygous individuals described and present in population databases suggests this variant may show reduced penetrance in the homozygous state. In summary, this variant meets the criteria to be classified as Pathogenic for autosomal recessive limb girdle muscular dystrophy based on the ACMG/AMP criteria applied, as specified by the ClinGen LGMD VCEP (LGMD VCEP specifications version 1.0.0; 01/09/2025): PVS1_RNA_Moderate, PM3_Very Strong, PP1_Moderate, PP4_Moderate. The LGMD VCEP recommends careful correlation with patient phenotype and family history as well as consideration of the combined functional impact of both CAPN3 alleles when the c.1746-20C>G variant is detected in an individual with signs of limb girdle muscular dystrophy. LINK:https://erepo.genome.network/evrepo/ui/classification/CA220343/MONDO:0015152/187

Frequency

Genomes: 𝑓 0.0031 ( 1 hom., cov: 32)
Exomes 𝑓: 0.0031 ( 14 hom. )

Consequence

CAPN3
NM_000070.3 intron

Scores

2

Clinical Significance

Pathogenic reviewed by expert panel P:4U:6B:5

Conservation

PhyloP100: 0.0590

Publications

23 publications found
Variant links:
Genes affected
CAPN3 (HGNC:1480): (calpain 3) Calpain, a heterodimer consisting of a large and a small subunit, is a major intracellular protease, although its function has not been well established. This gene encodes a muscle-specific member of the calpain large subunit family that specifically binds to titin. Mutations in this gene are associated with limb-girdle muscular dystrophies type 2A. Alternate promoters and alternative splicing result in multiple transcript variants encoding different isoforms and some variants are ubiquitously expressed. [provided by RefSeq, Jul 2008]
CAPN3 Gene-Disease associations (from GenCC):
  • autosomal recessive limb-girdle muscular dystrophy
    Inheritance: AR Classification: DEFINITIVE Submitted by: ClinGen
  • autosomal recessive limb-girdle muscular dystrophy type 2A
    Inheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Orphanet, Myriad Women’s Health, Labcorp Genetics (formerly Invitae)
  • muscular dystrophy, limb-girdle, autosomal dominant 4
    Inheritance: AD Classification: STRONG, MODERATE Submitted by: Ambry Genetics, Labcorp Genetics (formerly Invitae)
  • muscular dystrophy, limb-girdle, autosomal dominant
    Inheritance: AD Classification: LIMITED Submitted by: ClinGen

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Pathogenic. The variant received 8 ACMG points.

PVS1
For more information check the summary or visit ClinGen Evidence Repository.
PM3
For more information check the summary or visit ClinGen Evidence Repository.
PP1
For more information check the summary or visit ClinGen Evidence Repository.
PP4
For more information check the summary or visit ClinGen Evidence Repository.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
CAPN3NM_000070.3 linkc.1746-20C>G intron_variant Intron 13 of 23 ENST00000397163.8 NP_000061.1
CAPN3NM_024344.2 linkc.1746-20C>G intron_variant Intron 13 of 22 NP_077320.1
CAPN3NM_173087.2 linkc.1602-20C>G intron_variant Intron 12 of 20 NP_775110.1
CAPN3NM_173088.2 linkc.210-20C>G intron_variant Intron 2 of 12 NP_775111.1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
CAPN3ENST00000397163.8 linkc.1746-20C>G intron_variant Intron 13 of 23 1 NM_000070.3 ENSP00000380349.3
ENSG00000258461ENST00000495723.1 linkn.*2200-20C>G intron_variant Intron 16 of 25 2 ENSP00000492063.1

Frequencies

GnomAD3 genomes
AF:
0.00309
AC:
470
AN:
152174
Hom.:
1
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.000459
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.000524
Gnomad ASJ
AF:
0.00202
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.0115
Gnomad MID
AF:
0.00633
Gnomad NFE
AF:
0.00453
Gnomad OTH
AF:
0.00191
GnomAD2 exomes
AF:
0.00315
AC:
791
AN:
251486
AF XY:
0.00324
show subpopulations
Gnomad AFR exome
AF:
0.000246
Gnomad AMR exome
AF:
0.00119
Gnomad ASJ exome
AF:
0.00208
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.0100
Gnomad NFE exome
AF:
0.00426
Gnomad OTH exome
AF:
0.00342
GnomAD4 exome
AF:
0.00311
AC:
4534
AN:
1460084
Hom.:
14
Cov.:
30
AF XY:
0.00312
AC XY:
2268
AN XY:
726476
show subpopulations
African (AFR)
AF:
0.000179
AC:
6
AN:
33444
American (AMR)
AF:
0.00105
AC:
47
AN:
44712
Ashkenazi Jewish (ASJ)
AF:
0.00253
AC:
66
AN:
26122
East Asian (EAS)
AF:
0.0000252
AC:
1
AN:
39688
South Asian (SAS)
AF:
0.0000464
AC:
4
AN:
86220
European-Finnish (FIN)
AF:
0.00983
AC:
525
AN:
53386
Middle Eastern (MID)
AF:
0.00278
AC:
16
AN:
5760
European-Non Finnish (NFE)
AF:
0.00335
AC:
3716
AN:
1110426
Other (OTH)
AF:
0.00254
AC:
153
AN:
60326
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.452
Heterozygous variant carriers
0
240
480
719
959
1199
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
116
232
348
464
580
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.00309
AC:
470
AN:
152292
Hom.:
1
Cov.:
32
AF XY:
0.00314
AC XY:
234
AN XY:
74466
show subpopulations
African (AFR)
AF:
0.000457
AC:
19
AN:
41556
American (AMR)
AF:
0.000523
AC:
8
AN:
15292
Ashkenazi Jewish (ASJ)
AF:
0.00202
AC:
7
AN:
3472
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5188
South Asian (SAS)
AF:
0.00
AC:
0
AN:
4820
European-Finnish (FIN)
AF:
0.0115
AC:
122
AN:
10614
Middle Eastern (MID)
AF:
0.00680
AC:
2
AN:
294
European-Non Finnish (NFE)
AF:
0.00453
AC:
308
AN:
68030
Other (OTH)
AF:
0.00189
AC:
4
AN:
2114
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.493
Heterozygous variant carriers
0
25
51
76
102
127
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
10
20
30
40
50
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.00420
Hom.:
0
Bravo
AF:
0.00209

ClinVar

Significance: Pathogenic
Submissions summary: Pathogenic:4Uncertain:6Benign:5
Revision: reviewed by expert panel
LINK: link

Submissions by phenotype

not provided Pathogenic:2Uncertain:1Benign:2
Oct 01, 2022
CeGaT Center for Human Genetics Tuebingen
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

CAPN3: BS1, BS2 -

May 31, 2023
Institute for Clinical Genetics, University Hospital TU Dresden, University Hospital TU Dresden
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

PP4, PS3 -

Feb 16, 2025
Laboratory of Genetics, Children's Clinical University Hospital Latvia
Significance:Likely pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Jun 06, 2018
GeneDx
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is associated with the following publications: (PMID: 18055493, 28877744, 20635405, 17994539, 17979987, 17157502, 16141003, 16411092, 15351423, 16372320, 27447704, 27708273, 26886200, 27884173, 26301378, 28602176, 25135358, 18854869, 30028523, 30919934, 31788660, 32403337, 31127727) -

Jul 23, 2025
Athena Diagnostics
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The frequency of this variant in the general population is consistent with pathogenicity. This variant appears to segregate with autosomal recessive LGMD in at least one family. In multiple individuals presenting with LGMD, this variant has been seen with a single recessive pathogenic variant in the same gene, suggesting this variant may be pathogenic (PMID: 35731190, 34720847, 27447704, 24803842). However, this variant has also been detected homozygous in reportedly healthy individuals (PMID: 35731190, 27884173). Computational tools yielded predictions that this variant is unlikely to have an effect on normal RNA splicing. Experimental evidence regarding the impact of this variant on splicing is conflicting. This variant has been reported to alter normal mRNA splicing in some publications (PMID: 35731190, 20635405, 34863162), yet not in another (PMID: 17979987). However, all of these studies have methodological limitations and cannot be viewed as providing conclusive results. CAPN3 protein was found to be absent or significantly reduced in samples taken from multiple individuals carrying this variant (PMID: 34720847, 20635405). Most pathogenic variants in CAPN3 (OMIM * 114240) are associated with autosomal recessive limb-girdle muscular dystrophy (LGMD), however some cases of dominant segregation have also been reported (PMID: 32896923, 30564623, 27259757, 28881388). -

Autosomal recessive limb-girdle muscular dystrophy type 2A Uncertain:2Benign:1
Dec 18, 2017
Counsyl
Significance:Uncertain significance
Review Status:no assertion criteria provided
Collection Method:clinical testing

This submission and the accompanying classification are no longer maintained by the submitter. For more information on current observations and classification, please contact variantquestions@myriad.com. -

Apr 17, 2020
Natera, Inc.
Significance:Uncertain significance
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Feb 02, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Autosomal recessive limb-girdle muscular dystrophy Pathogenic:1Uncertain:1
Jan 09, 2025
ClinGen Limb Girdle Muscular Dystrophy Variant Curation Expert Panel, ClinGen
Significance:Pathogenic
Review Status:reviewed by expert panel
Collection Method:curation

The NM_000070.3: c.1746-20C>G variant occurs in intron 13 of the CAPN3 gene. The filtering allele frequency for this variant is 0.006051 in gnomAD v2.1.1 European (non-Finnish) genomes (the lower threshold of the 95% CI of 172/31388), which is higher than the LGMD VCEP threshold of 0.001 for BS1; in total, three homozygous individuals are also observed. However, this variant may act as a hypomorphic allele, and the VCEP opted not to apply this code (BS1 exception). RNAseq/cDNA analysis of muscle from patients carrying one copy of the variant suggests that it results in aberrant splicing, the inclusion of various portions of intron 13, and premature truncation (PMID: 20635405, 35731190). An earlier study concluded the variant does not affect splicing (PMID: 17979987); however, later investigations showed that the aberrantly spliced transcripts are variably expressed and not always detectable even when splicing-specific PCR is used, possibly due to nonsense-mediated mRNA decay (PMID: 20635405) (PVS1_RNA_Moderate). The c.1746-20C>G variant has been detected with a second CAPN3 variant in at least 34 individuals with LGMD (PMID: 37589857, 20635405, 17979987, 17157502, 35731190), including confirmed in trans with a pathogenic variant in five cases (c.550delA p.(Thr184ArgfsTer36), 4.0 pts, PMID: 20635405, 35731190; c.643_663del p.(Ser215_Gly221del): 1.0 pt, PMID: 35731190) (PM3_Very Strong). The variant was also reported to co-segregate with autosomal recessive disease in four affected family members from three families (PP1_Moderate; PMID: 37589857, 20635405, 35731190). Several patients with the c.1746-20C>G variant and a second CAPN3 variant displayed progressive limb girdle muscle weakness or clinical suspicion of limb-girdle muscular dystrophy as well as significantly reduced or absent expression of calpain-3, which is specific for CAPN3-related LGMD (PP4_Moderate; PMID: 20635405). While two homozygous patients with a mild phenotype have been reported (PMID: 35731190), the number of apparently unaffected homozygous individuals described and present in population databases suggests this variant may show reduced penetrance in the homozygous state. In summary, this variant meets the criteria to be classified as Pathogenic for autosomal recessive limb girdle muscular dystrophy based on the ACMG/AMP criteria applied, as specified by the ClinGen LGMD VCEP (LGMD VCEP specifications version 1.0.0; 01/09/2025): PVS1_RNA_Moderate, PM3_Very Strong, PP1_Moderate, PP4_Moderate. The LGMD VCEP recommends careful correlation with patient phenotype and family history as well as consideration of the combined functional impact of both CAPN3 alleles when the c.1746-20C>G variant is detected in an individual with signs of limb girdle muscular dystrophy. -

May 02, 2023
Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:curation

The heterozygous c.1746-20C>G variant in CAPN3 was identified by our study, in the compound heterozygous state with a pathogenic variant (ClinVar Variation ID: 166786) in one individual with limb girdle muscular dystrophy (Broad Institute Rare Genomes Project). Familial exome analysis revealed that this variant was in trans with a pathogenic variant (ClinVar Variation ID: 166786). The c.1746-20C>G variant in CAPN3 has been previously reported in 19 individuals with autosomal recessive limb-girdle muscular dystrophy 1 (PMID: 30028523, PMID: 27708273, PMID: 27447704, PMID: 28877744, PMID: 28602176, PMID: 26886200, PMID: 18854869, PMID: 18055493, PMID: 16141003, PMID: 17994539, PMID: 16411092, PMID: 17157502, PMID: 17979987) and segregated with disease in two affected individuals from one family (PMID: 27708273), but has been identified in 1.1% (122/10614) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP ID: rs201892814). This variant has been seen in the general population, in a heterozygous state, at greater rate than expected for disorder. This variant has also been reported in ClinVar (Variation ID: 92408) and has conflicting interpretations. Of the 19 affected individuals reported (PMID: 30028523, PMID: 27708273, PMID: 27447704, PMID: 28877744, PMID: 28602176, PMID: 26886200, PMID: 18854869, PMID: 18055493, PMID: 16141003, PMID: 17994539, PMID: 16411092, PMID: 17157502, PMID: 17979987), one was a homozygote (PMID: 16411092), six were compound heterozygotes who carried pathogenic or likely pathogenic variants in trans (PMID: 18854869, ClinVar Variation ID: 17621, ClinVar Variation ID: 282783; PMID: 26886200, ClinVar Variation ID: 282783; PMID: 28877744, ClinVar Variation ID: 197624; PMID: 2744770, ClinVar Variation ID: 282783, ClinVar Variation ID: 166786), three were presumed compound heterozygotes who carried pathogenic or likely pathogenic variants in unknown phase (PMID: 17157502, ClinVar Variation ID: 166786; PMID: 28602176, PMID: 30028523, ClinVar Variation ID: 813980) and four were compound heterozygotes who carried variants of uncertain significance in trans (PMID: 17994539, PMID: 18854869; PMID: 27708273), which increases the likelihood that the c.1746-20C>G variant is pathogenic. RT-PCR analyses performed on affected tissue are conflicting regarding whether this variant impacts splicing (PMID: 17979987, PMID: 20635405). This variant is located in the 3’ splice region. Computational tools do suggest an impact to splicing. However, this information is not predictive enough to determine pathogenicity. In summary, the clinical significance of the c.1746-20C>G variant is uncertain. ACMG/AMP Criteria applied: PM3_VeryStrong, BS1, PP1_moderate (Richards 2015). -

not specified Benign:2
Nov 23, 2016
Eurofins Ntd Llc (ga)
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Jan 06, 2022
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Variant summary: CAPN3 c.1746-20C>G alters a non-conserved nucleotide located close to a canonical splice site and therefore could affect mRNA splicing, leading to a significantly altered protein sequence. 4/4 computational tools predict no significant impact on normal splicing. This is confirmed by one study reporting no impact on splicing (example, Krahn_2007). In another study. the average value for amount of CAPN3 transcripts relative to three housekeeping genes using CAPN3 mRNA of a patient without splice variant as calibrator, showed the levels of transcript in a patient with this variant in a compound heterozygous genotype did not differ significantly from the control values (example, Stehlikova_2007). The variant allele was found at a frequency of 0.0031 in 251486 control chromosomes, predominantly at a frequency of 0.0043 within the Non-Finnish European subpopulation in the gnomAD database, including 2 homozygotes. This variant is among those re-classified as benign based on lack of phenotype in homozygotes (ACMG BS2-only variants) (example, Abouelhoda_2016). The observed variant frequency within Non-Finnish European control individuals in the gnomAD database is approximately 1.3 fold of the estimated maximal expected allele frequency for a pathogenic variant in CAPN3 causing Limb-Girdle Muscular Dystrophy, Autosomal Recessive phenotype (0.0032), strongly suggesting that the variant is a benign polymorphism found primarily in populations of Non-Finnish European origin. c.1746-20C>G has been reported in the literature as a non-informative genotype in numerous compound heterozygous patients undergoing testing for limb girdle muscular dystrophy via panel/exome/single gene analysis (example, Piluso_2005, Krahn_2007, Stehlikova_2007, Nascimbeni_2010, Avila_2015, Harris_2017, Reddy_2017). In at-least one of these reports it was found to co-occur in cis with a different allele (c.1745+4_1745+7delAGTG) that was characterized by complementary DNA analysis as having a pathogenic outcome (example, Krahn_2007). These report(s) do not provide unequivocal conclusions about association of the variant with Limb-Girdle Muscular Dystrophy type 2A, Autosomal Recessive. To our knowledge, no variant specific experimental evidence demonstrating an impact on protein function has been reported. Seven clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. Multiple laboratories reported the variant with conflicting assessments. Based on the evidence outlined above, the variant was classified as benign. -

Paresthesia;C0149931:Migraine;C0240914:Positive Romberg sign;C0241005:Elevated circulating creatine kinase concentration;C0311394:Difficulty walking;C4021727:EMG: neuropathic changes;C4022625:Absent muscle fiber calpain-3;C4082951:Progressive spinal muscular atrophy Pathogenic:1
Jan 01, 2017
Centre for Mendelian Genomics, University Medical Centre Ljubljana
Significance:Pathogenic
Review Status:flagged submission
Collection Method:clinical testing

- -

Autosomal recessive limb-girdle muscular dystrophy type 2A;C4748295:Muscular dystrophy, limb-girdle, autosomal dominant 4 Uncertain:1
Aug 29, 2023
Department of Pathology and Laboratory Medicine, Sinai Health System
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:research

- -

See cases Uncertain:1
Jul 15, 2024
Institute of Human Genetics, University Hospital Muenster
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

ACMG categories: PM3,BS2 -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.83
CADD
Benign
1.7
DANN
Benign
0.59
PhyloP100
0.059
Mutation Taster
=24/64
disease causing (ClinVar)

Splicing

Name
Calibrated prediction
Score
Prediction
Splicevardb
3.0
SpliceAI score (max)
0.13
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs201892814; hg19: chr15-42695919; API